Eagle Pharmaceuticals Inc (EGRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eagle Pharmaceuticals Inc (EGRX) has a cash flow conversion efficiency ratio of 0.000x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-126.00K) by net assets ($252.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Eagle Pharmaceuticals Inc balance sheet independence to measure how much of total assets are equity-financed.
Eagle Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2012–2022)
This chart illustrates how Eagle Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Eagle Pharmaceuticals Inc to evaluate the quality of earnings relative to operating cash generation.
Eagle Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eagle Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Harris Technology Group Ltd
AU:HT8
|
-0.192x |
|
Marvel Discovery Corp
V:MARV
|
0.000x |
|
NOROO Paint & Coatings Co Ltd
KO:090355
|
-0.006x |
|
Labat Africa Ltd
JSE:LAB
|
0.005x |
|
Kane Biotech Inc
V:KNE
|
0.912x |
|
MT Malcolm Mines NL
AU:M2M
|
-0.056x |
|
New Zealand Coastal Seafoods Ltd
AU:NZS
|
-0.786x |
|
Alvo Minerals Ltd
AU:ALV
|
-2.176x |
Annual Cash Flow Conversion Efficiency for Eagle Pharmaceuticals Inc (2012–2022)
The table below shows the annual cash flow conversion efficiency of Eagle Pharmaceuticals Inc from 2012 to 2022. For the full company profile with market capitalisation and key ratios, see market cap of Eagle Pharmaceuticals Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $233.56 Million | $30.80 Million | 0.132x | -17.55% |
| 2021-12-31 | $176.45 Million | $28.22 Million | 0.160x | -39.90% |
| 2020-12-31 | $186.01 Million | $49.50 Million | 0.266x | -14.84% |
| 2019-12-31 | $179.17 Million | $55.99 Million | 0.312x | -4.11% |
| 2018-12-31 | $160.76 Million | $52.38 Million | 0.326x | -0.93% |
| 2017-12-31 | $179.14 Million | $58.92 Million | 0.329x | -6.52% |
| 2016-12-31 | $151.23 Million | $53.21 Million | 0.352x | +427.08% |
| 2015-12-31 | $90.34 Million | $-9.72 Million | -0.108x | +74.28% |
| 2014-12-31 | $33.10 Million | $-13.84 Million | -0.418x | +85.39% |
| 2013-12-31 | $2.05 Million | $-5.88 Million | -2.863x | -322.75% |
| 2012-12-31 | $-12.10 Million | $-15.55 Million | 1.285x | -- |
About Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non… Read more